Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Sawai Grabs Japan Rights to CureApp’s NASH Therapeutic App
Sawai Group Holdings said on August 2 that will acquire exclusive Japan development and marketing rights of the therapeutic app for non-alcoholic steatohepatitis (NASH) developed by Tokyo-based health tech CureApp. The app is anticipated to be prescribed by physicians. Under…
To read the full story
Related Article
- Sawai Eyes Digital and Device Business as Next Growth Pillar after Generics
December 2, 2025
- Sawai Nabs Distribution Rights to CureApp’s Alcoholism Therapy App
August 29, 2024
- CureApp Kicks Off Japan PIII Study for NASH Therapeutic App
February 21, 2024
BUSINESS
- Teijin to Divest Feburic, Bonalon, Other Legacy Brands to LTL
June 18, 2026
- Takeda CEO Pulls in 2.3 Billion Yen in FY2025
June 18, 2026
- Sawai’s Revlimid Generic Gains Additional Lymphoma Indications
June 18, 2026
- Efient AGs Widen Labels to Close Indication Gap
June 18, 2026
- AZ, Kyoto Ink Pact to Promote NCD Prevention, Early Detection
June 18, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…